David Heredia, Thoracic oncologist at Punta Médica Hospital, posted on X:
“Not all Lung adenocarcinomas (LUAD) respond the same.
Mucinous LUAD = 10% of cases, often KRAS+, TTF1–, PD-L1 low
Worse outcomes across therapies:
- ICI ORR: 8.4% vs 25.9%
- IO+chemo OS: 11.4 vs 19.6 mo
- KRASG12C OS: 6.8 vs 10.8 mo
Histology matters.”
“Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.”
Authors: A. Di Federico et al.
